GW’s Cannabidiol Drug To Be Funded In England For Epilepsy
More Data To Be Provided On Benefits And Safety
Executive Summary
GW Pharma’s cannabidiol drug Epidyolex can be funded on the NHS in England for seizures in patients with Dravet syndrome or Lennox-Gastaut syndrome. The company will have to provide additional data to address a number of uncertainties, including the waning of treatment effect, while more safety data are expected from an ongoing study.